News

Short-course fluoroquinolone treatment is as effective as the conventional 7-day course for acute exacerbations of chronic ...
Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to ...
More than 80 million people in Europe are affected, and many more are undiagnosed, with primary care practitioners ill-prepared to identify the conditions.
Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...
Newly released Medicare national coverage determinations are set to reshape the home ventilation landscape for chronic ...
Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study ...
As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the ...
According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...
People with one of more than 20 breathing conditions could be eligible for up to £749 a month from the Department for Work ...
New Partnership with Leonard Nimoy’s Daughter Aims to Raise COPD Awareness ...
as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD). Nucala stands out as the only approved biologic that has been ...
A 6-minute walk of less than 350 meters tripled the mortality risk, whereas chronic kidney disease (CKD) independently ...